Scientific Program

8th Asian Biologics and Biosimilars Congress

August 10-12, 2017    Beijing, China
Day 1  August 10, 2017

Hall

conference-series.com  09:30-09:40 Opening Ceremony

Keynote Forum

09:40-09:45 Introduction
09:45-10:35 Title: FDA/EMA current thinking on totality of evidence for development of biosimilars
Kamali Chance, Vice President, Quintiles, IMS, USA
10:35-11:25 Title: Strategic partnership for China biologics
Jianguo Yang, President / CEO, Abspco China, USA

Group Photo

Networking & Refreshment Break: 11:25-11:50

11:50-12:40 Title: Biosimilars: Accelerating early clinical development
Raymond Huml, Vice President, Quintiles IMS, USA

Sessions:
Challenges in Developing Biosimilars | Cost Analysis of Biosimilars | Emerging Trends in Biosimilars | Emerging Biosimilars in Therapeutics

Session Chair: Darius Panaligan, Vice President, Global Head of Commercial at Merck Group, Switzerland
Session Co-Chair: Hossein Pakdaman, President of Iranian Neurological Association, Iran

13:40-14:10 Title: Challenges in assessing therapeutic equivalence of nano-similars
Beat Fluehmann, Director Vifor Pharma Ltd, Switzerland
14:10-14:40 Title: Challenges and opportunities in biosimilar commercialization
Darius Panaligan, Vice President, Global Head of Commercial at Merck Group, Merck Biosimilars, Switzerland
14:40-15:10 Title: Convergence of regulatory expectations
Robert Salcedo, President and Founder at Biosimilars Solutions and BioSciencesCorp, USA

Networking & Refreshment Break: 15:10-15:30

15:30-16:00 Title: From neuromodulation to drug discovery and treatment
Luis Ulloa, Professor of Surgery, Rutgers University- New Jersey Medical School, USA
16:00-16:30 Title: The role of regulatory policies in relation to the local biosimilars production
Gustavo H Marin, Head Professor at UNLP-CONICET, Argentina

Day 1 Ends

Day 2  August 11, 2017

Hall

Keynote Forum

10:00-10:05 Introduction
10:05-10:55 Title: Strategy for the global development of biosimilars: Putting it’s all together
Oxana Iliach, Sr. Director Quintiles IMS, Canada

Networking & Refreshment Break: 10:55-11:25

11:25-12:15 Title: Clinical development of biosimilars for Western markets: Planning for success
Charu Manaktala, Senior Medical Director Quintiles IMS, India

Sessions:
Globalization of Biosimilars | Biosimilars Market Challenges & Prospects | Pharmacovigilance of Biosimilars

Session Chair: Robert Salcedo, President and Founder at Biosimilars Solutions and BioSciencesCorp, USA
Session Co-Chair: Hossein Pakdaman, President of Iranian Neurological Association, Iran

13:15-13:45 Title: 10 year perspective: science and commercial power. Battle of the giants in biosimilars
Richard Littlewood, CEO Founder at appliedstrategic, London, UK
Title: Biosimilars in the UK’s NHS: Attitudes, appetites and acceptance
Divya Chadha Manek, Head of Commercial Business Development, NHR, UK

Title: Comparison of biosimilar registration guidelines between EU and USA
Frank Cheng, Founder and principle senior consultant, Alban Pharma, Hong Kong

Special Session
14:45-15:25
Title: Biosimilars: Challenges in safety and risk management
Asif Mahmood, Disease Area Cluster Lead for Biosimilars Pfizer, USA

Poster Presentation @ 15:55-16:35
BS-01
Title: Theodor bilharz research institute therapeutic products and health tools
Ismaeil Saad, Professor, Theodor Bilharz Research Institute (TBRI), Giza

BS-02
Title: Some considerations about biosimilar safety
Samer M Al-Hulu, PhD, Al-Qasim Green University, Iraq
Title: Biosimilars: Overview, evolution and regulations assessment systematic development, regulations and molecules approved in Australia, Brazil, Malaysia, Japan, Singapore and South Korea
Tomas Gabriel BAS, PhD, Coquimbo, Chile


Day 2 Ends

Day 3 August 12, 2017
Hall

Keynote Forum
10:00-10:05
Introduction

10:05-10:55
Title: Biosimilars in treatment of multiple sclerosis
Hossein Pakdaman, President of Iranian Neurological Association, Iran

Sessions:
Emerging Biosimilars in Therapeutics | Clinical Studies on Biosimilars

Session Introduction
Title: Practical considerations in clinical strategy to support the development of biologics device combination products
Zhaoyang Li, Director Sanofi
Title: Expression of shiga-like toxin fused to vascular endothelial growth factor in E.coli for targeting angiogenesis
Osama O Ibrahim, Consultant Biotechnology/ Food Safety Bioinnovation, USA

Lunch Break: 12:00-13:00

Networking and Closing Ceremony